Image

Asia-Pacific Bronchiectasis Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 325
  • No of Figures: 56
  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 325
  • No of Figures: 56

Asia-Pacific Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific Bronchiectasis Market Market Analysis and Insights : Asia-Pacific Bronchiectasis Market

Asia-Pacific bronchiectasis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.5% in the forecast period of 2021 to 2028 and is expected to reach USD 186.19 million by 2028. Technological advancement for disease testing and raising number of smokers and consumption of alcohol are the major drivers which propelled the demand of the market in the forecast period.

Bronchiectasis comprises features such increasing need for safe and effective product will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative bronchiectasis products which is expected to provide various other opportunities in the bronchiectasis market. However, product recalls and complications in the treatment of bronchiectasis expected to restraint the market growth in the forecast period.

Bronchiectasis is a condition which leads to damage of lungs airways that is infection and inflammation occurs in the path were air comes in and out. The mucus gets collected in the airways which get clogged and bacteria start to grow in that region which leads to bronchiectasis. When this mucus gets collected in the airways and is not early diagnosed and treated it may cause damage to the lungs. This condition mainly occurs in women population and in the United States it was recorded that children with whooping cough generally have bronchiectasis.

Bronchiectasis can be congenital or acquired. The acquired one occurs mainly in infants and children whereas congenital occurs in adults. Cystic fibrosis, immunodeficiency disorders, allergic bronchopulmonary aspergillosis, and primary ciliary dyskinesia are some of the risk factors for bronchiectasis. Mainly antibiotics and oxygen therapies are recommended by the doctors and the patients have to live the condition as there is no permanent cure for the disease.

The Bronchiectasis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Bronchiectasis Market Asia-Pacific Bronchiectasis Market Scope and Market Size

Bronchiectasis market is segmented on the based on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the bronchiectasis market is segmented into non-CF bronchiectasis and CF bronchiectasis. In 2021, non-CF bronchiectasis is expected to dominate the bronchiectasis market as it is the most common form of bronchiectasis which has been reported to affect most of the women and adult population.
  • On the basis of severity, the bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the bronchiectasis market because bronchiectasis is a progressive respiratory disorder which is characterized by abnormally dilated airways, excessive sputum production and recurrent pulmonary infections among other symptoms which can be treated by novel drugs and other therapies.
  • On the basis of type, the bronchiectasis market is segmented into treatment and diagnosis. In 2021, treatment segment is expected to dominate the bronchiectasis market because bronchiectasis is the long term chronic disease and affected patient population are largely dependent on drugs in order to lead a healthy life.
  • On the basis of drugs type, the bronchiectasis market is segmented into branded and generic. In 2021, branded segment is expected to dominate the bronchiectasis market as most of the companies are engaged in manufacturing of branded drugs. Moreover increasing demand of safe product raises the demand of branded drugs among patient population.
  • On the basis of route of administration, the bronchiectasis market is segmented into oral, parenteral, and inhalation. In 2021, inhalation segment is expected to dominate the bronchiectasis market because bronchiectasis is a lung associated inflammatory disease which can rapidly treat with drugs directly targeting lung airways.  
  • On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare, and others. In 2021, hospitals segment is dominating the bronchiectasis market because hospitals have advanced diagnostic tools used for accurate diagnosis of bronchiectasis. Moreover skilled professionals at hospitals allow effective intravenous drug delivery which acts as another factor boosting the market growth.
  • On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy is expected to dominate the bronchiectasis market as hospital pharmacy have has wide range of products as per the patients need and demand.

Bronchiectasis Market Country Level Analysis

The bronchiectasis market is analyzed and market size information is provided on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.

The countries covered in the bronchiectasis market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific.

Treatment segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because bronchiectasis is the life-long disease and required continuous treatment. The overall treatment cost for the bronchiectasis is quite high and now consider in some reimbursement policies. Japan is leading the growth of the Asia-Pacific market and treatment segment is dominating in this country due to technological advancement for the diagnosis and treatment of respiratory diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Technological Advancement for Disease Testing and Increase in Research Regarding the Bronchiectasis Disease are Boosting the Market Growth of Bronchiectasis

Bronchiectasis market also provides you with detailed market analysis for every country growth in bronchiectasis industry with bronchiectasis drugs sales, impact of advancement in the bronchiectasis technology and changes in regulatory scenarios with their support for the bronchiectasis market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Bronchiectasis Market Share Analysis

Bronchiectasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to bronchiectasis market.

The major companies which are dealing in the bronchiectasis are Abbott, HERSILL, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos S.A., Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy’s Laboratories Ltd., Viatris Inc. and Cipla Inc., among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the bronchiectasis market.

  • In December 2018, AstraZeneca received approval for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) indicated for treatment of severe symptoms associated with COPD. This product has already received approval by regulatory authorities of Canada, the U.S, Australia, Taiwan and Turkey. This new approval enhanced the product sales which has positively impacted the company’s revenue.
  • In February 2018, GlaxoSmithKline plc. launched Flunase, in Japan. Flunase is the first fluticasone propionate-based treatment launched in Japan and is indicated for relieving the inflammatory symptoms associated with respiratory problems. This product launch thus allowed the company to fulfil the unmet patients demand suffering from bronchiectasis in Japan and boosted the company’s revenue by positive increase of product sales.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the bronchiectasis market which also provides the benefit for organization to improve their offering for bronchiectasis.


SKU-

Why Choose Us


Frequently Asked Questions